CARLSBAD, Calif., June 07, 2021 (GLOBE NEWSWIRE) — Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology firm growing therapies for degenerative genetic problems, right this moment introduced the appointments of business veterans, Heather Behanna, Ph.D., principal of SR One, and Deepa Prasad, managing director of WestRiver Group, to its board of administrators efficient June 15, 2021.
“We’re delighted to additional strengthen the Design staff with the appointments of each Heather and Deepa to our board of administrators, who convey a wealth of expertise and insights in company and monetary technique and biotechnology firm progress,” mentioned João Siffert, M.D., president and chief government officer of Design Therapeutics. “Over the course of 2021, we have now continued to progress our pipeline of novel GeneTAC™ therapeutic candidates, and their experience might be invaluable as we glance to make the vital transition to a clinical-stage firm with the anticipated initiation of scientific improvement for our Friedreich ataxia program within the first half of subsequent 12 months.”
Dr. Behanna presently serves as a principal at SR One Capital Administration, concentrating on early-stage modern therapeutic alternatives. Dr. Behanna is presently a board member of Second Genome and Entasis Therapeutics (ETTX) and a board observer of Dren Bio. Previous to SR One, she was with Sofinnova Investments, and previous to that, was an fairness analysis analyst at Wedbush and JMP Securities, centered totally on therapies for uncommon illness. Dr. Behanna was previously a chemist on the Astellas Analysis institute and adjunct college on the Feinberg Northwestern Faculty of Drugs. Dr. Behanna obtained her Ph.D. in chemistry at Northwestern College, MSc. in natural chemistry on the Weizmann Institute of Science and B.S. from Tufts College.
“Friedreich ataxia is devastating, with no treatment or accepted disease-modifying remedy choice right this moment. I’m extremely inspired by the chance enabled by Design’s strategy to deal with the underlying reason for this illness,” mentioned Dr. Behanna. “I stay up for working alongside your entire staff to assist information the enterprise technique and improvement plans, in order that we might doubtlessly ship the primary remedy to extend endogenous frataxin for sufferers with Friedreich ataxia.”
Ms. Prasad presently serves as a managing director at WestRiver Group (WRG), the place she leverages her greater than 20 years of investing and working expertise to concentrate on investments in healthcare innovation throughout biotech and digital well being and synthetic intelligence. Previous to WRG, Ms. Prasad served as chief of employees at Blue Defend, regional vice chairman and common supervisor for Optum, head of managed care on the California Hospital Affiliation, and Coherus Biosciences (CHRS) the place she led monetary technique and enterprise improvement. She started her profession in funding banking working with biotech and pharma firms on personal placements and buyside and sellside mergers and acquisitions. She presently serves on the Grant Funding Committee for UC Davis and as a constitution member for TiE, a non-profit world community of entrepreneurs and enterprise capitalists. Ms. Prasad earned her bachelor’s diploma in enterprise administration on the College of California, Berkeley and her M.B.A. from the Kellogg Faculty of Administration at Northwestern College with emphasis in finance and well being business administration.
“Design’s proprietary GeneTAC platform has a singular alternative to deal with the foundation reason for genetic ailments pushed by inherited nucleotide repeat expansions and make a major impression on the lives of these affected,” mentioned Ms. Prasad. “The staff has made exceptional progress since its founding in 2017, and I’m happy to associate with the Design staff and board of administrators, in order that we might convey ahead a brand new class of small molecule therapeutics that present a doubtlessly disease-modifying remedy for these sufferers.”
About Design Therapeutics
Design Therapeutics is a biotechnology firm growing a brand new class of therapies based mostly on a platform of gene focused chimera (GeneTAC™) small molecules. Our GeneTAC molecules are designed to both activate or flip off a selected disease-causing gene to deal with the underlying reason for illness. The corporate’s lead program is concentrated on the remedy of Friedreich ataxia, adopted by a program in myotonic dystrophy type-1 and discovery efforts for a number of different severe degenerative problems brought on by nucleotide repeat expansions. For extra data, please go to designtx.com.
Ahead Trying Statements
Statements on this press launch that aren’t purely historic in nature are “forward-looking statements” throughout the which means of the Personal Securities Litigation Reform Act of 1995. These statements embody, however aren’t restricted to, statements associated to: the progress and anticipated timing of Design’s improvement packages and any scientific trials; the effectiveness of Design’s GeneTAC program within the remedy of Friedreich ataxia and myotonic dystrophy type-1; and the potential benefits of those GeneTAC packages. As a result of such statements are topic to dangers and uncertainties, precise outcomes might differ materially from these expressed or implied by such forward-looking statements. Phrases comparable to “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “objective,” “potential” and comparable expressions are supposed to establish forward-looking statements. These forward-looking statements are based mostly upon Design’s present expectations and contain assumptions that will by no means materialize or might show to be incorrect. Precise outcomes and the timing of occasions may differ materially from these anticipated in such forward-looking statements because of varied dangers and uncertainties, which embody, with out limitation, dangers related to the method of discovering, growing and commercializing therapies which are protected and efficient to be used as human therapeutics and working as a improvement stage firm; Design’s potential to develop, provoke or full preclinical research and scientific trials for, get hold of approvals for and commercialize any of its product candidates; the danger that early analysis or scientific trials don’t show security and/or efficacy in later preclinical research or scientific trials; uncertainties related to performing scientific trials, regulatory filings and functions; modifications in Design’s plans to develop and commercialize its product candidates; Design’s potential to lift any further funding it might want to proceed to pursue its enterprise and product improvement plans; regulatory developments in the USA and international international locations; Design’s reliance on key third events, together with contract producers and contract analysis organizations; Design’s potential to acquire and keep mental property safety for its product candidates; the lack of key scientific or administration personnel; competitors within the business during which Design operates; and common market situations. For a extra detailed dialogue of those and different elements, please consult with Design’s filings with the Securities and Alternate Fee. You might be cautioned to not place undue reliance on these forward-looking statements, which communicate solely as of the date hereof. All forward-looking statements are certified of their entirety by this cautionary assertion and Design undertakes no obligation to revise or replace this press launch to mirror occasions or circumstances after the date hereof, besides as required by legislation.
THRUST Strategic Communications